Efficacy and Safety of AJU-C52 in Essential Hypertension Patients
NCT ID: NCT06416865
Last Updated: 2024-05-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
190 participants
INTERVENTIONAL
2022-06-27
2024-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52L in Healthy Volunteers
NCT05077475
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy
NCT05526703
A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy
NCT02368652
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension
NCT04686643
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
NCT05503953
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AJU-C52L, AJU-C52
Treatment Period 1: AJU-C52L+C52R1L placebo
Treatment Period 2: AJU-C52+C52R1M placebo
AJU-C52L, AJU-C52
AJU-C52L+C52R1L placebo: Subjects take the investigational products once a day for 2 weeks.
AJU-C52+C52R1M placebo: Subjects take the investigational products once a day for 6 weeks.
C52R1L, C52R1M
Treatment Period 1: C52R1L+AJU-C52L placebo
Treatment Period 2: C52R1M+AJU-C52 placebo
C52R1L, C52R1M
C52R1L+AJU-C52L placebo: Subjects take the investigational products once a day for 2 weeks.
C52R1M+AJU-C52 placebo: Subjects take the investigational products once a day for 6 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AJU-C52L, AJU-C52
AJU-C52L+C52R1L placebo: Subjects take the investigational products once a day for 2 weeks.
AJU-C52+C52R1M placebo: Subjects take the investigational products once a day for 6 weeks.
C52R1L, C52R1M
C52R1L+AJU-C52L placebo: Subjects take the investigational products once a day for 2 weeks.
C52R1M+AJU-C52 placebo: Subjects take the investigational products once a day for 6 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Those who voluntarily signed the informed consent to participate in this study.
* A patient diagnosed with essential hypertension or Patients taking hypertension medication
* Those who are eligible for adequate blood pressure criteria during screening tests: Naïve patient-160 mmHg≤MSSBP\<200 mmHg and MSDBP\<110 mmHg/Patients taking hypertension medication-140 mmHg≤MSSBP\<200 mmHg and MSDBP\<110 mmHg
Exclusion Criteria
* Secondary hypertension patients or those with a history of suspected secondary hypertension
* Cardiovascular/cerebrovascular disease
* Those with a history of malignant tumor within 5 years
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AJU Pharm Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AJU Pharm Co., Ltd.
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21HT30601
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.